Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1146577 | 1.00 | TLR7 (1.00) | TLR7 | |
| SCHEMBL1146061 | 0.97 | TLR7 (1.00) | TLR7 | |
| SCHEMBL1146374 | 0.96 | TLR7 (1.00) | TLR7 | |
| SCHEMBL26347160 | 0.91 | TLR7 (0.84) | TLR7 | |
| SCHEMBL1145701 | 0.86 | TLR7 (0.79) | TLR7 | |
| SCHEMBL1145698 | 0.85 | TLR7 (1.00) | TLR7 | |
| SCHEMBL1146490 | 0.85 | TLR7 (1.00) | TLR7 | |
| SCHEMBL1146261 | 0.85 | TLR7 (0.73) | TLR7 | |
| SCHEMBL20756317 | 0.84 | TLR7 (0.73) | TLR7 | |
| SCHEMBL17417198 | 0.84 | TLR7 (1.00) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 512 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665402-A1 | COPOLYMER-DRUG CONJUGATE FOR TREATMENT OF TUMOURS | Danmarks Tekniske Universitet (DK) | 2025-12-24 | — | — | EP | claimed |
| US-20250270316-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | TIANJIN LIPOGEN TECH CO LTD (CN) | 2025-08-28 | — | — | US | claimed |
| WO-2025010407-A2 | NANOSCALE METAL-ORGANIC FRAMEWORKS WITH X-RAY TRIGGERABLE PRODRUGS FOR COMBINATION RADIOTHERAPY, CHEMOTHERAPY, AND IMMUNOTHERAPY | THE UNIVERSITY OF CHICAGO (US) | 2025-01-09 | — | — | WO | claimed |
| WO-2024170742-A1 | COPOLYMER-DRUG CONJUGATE FOR TREATMENT OF TUMOURS | DANMARKS TEKNISKE UNIVERSITET (DK) | 2024-08-22 | — | — | WO | claimed |
| CN-117881419-A | Pharmaceutical combination and use thereof | 天津立博美华基因科技有限责任公司 | 2024-04-12 | — | — | CN | claimed |
| US-11773098-B2 | Solid forms of a toll-like receptor modulator | GILEAD SCIENCES, INC. (US) | 2023-10-03 | — | — | US | claimed |
| WO-2023274275-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | 天津立博美华基因科技有限责任公司 | 2023-01-05 | — | — | WO | claimed |
| CN-122055369-A | Bridged tricyclic carbamoyl pyridone compounds and uses thereof | 吉利德科学公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-122055373-A | Bridged tricyclic carbamoyl pyridone compounds and uses thereof | 吉利德科学公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-122036801-A | Crystalline forms of tenofovir alafenamide | 吉利德科学公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20260130893-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| CN-122005785-A | Method for identifying HIV patients susceptible to therapy with GP 120V 3 glycan-directed antibodies | 吉利德科学公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4735445-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-3972645-A1 | METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH GP120 V3 GLYCAN-DIRECTED ANTIBODIES | Gilead Sciences, Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| CN-114245807-A | FLT3L-FC fusion proteins and methods of use | 吉利德科学公司 | 2022-03-25 | — | — | CN | disclosed |
| US-20220073473-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2022-03-10 | — | — | US | disclosed |
| WO-2022046644-A1 | MULTI-SPECIFIC ANTIGEN BINDING MOLECULES TARGETING HIV AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022040596-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2022-02-24 | — | — | WO | disclosed |
| US-20220049021-A1 | FLT3L-Fc FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES, INC. | 2022-02-17 | — | — | US | disclosed |
| US-11236085-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073473-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | TLR8, TLR3, TLR6 | TLR7 9/4885 |
| US-20260130893-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | TLR7 4000/4885 |
| US-11773098-B2 | Solid forms of a toll-like receptor modulator | TLR4, TLR3, TLR6 | TLR7 6/4885 |
| US-11236085-B2 | PD-1/PD-L1 inhibitors | PDCD1, CD274, PDCD1LG2 | TLR7 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.